CVI is a spectrum of visual impairments due to brain abnormalities affecting visual processing pathways, distinct from ocular ...

In the second case, Scott D. Walter, MD, MSc, FASRS presents a patient case of diabetic macular edema (DME) where each eye was treated with a different agent. Walter presents optical coherence ...

Sumit Sharma, MD, FASRS ponders to the panel the root cause of improved outcomes with newer agents. The panel then highlights current gaps in measuring visual improvements beyond tools such as the OCT ...

Both LUNA and OPTIC were designed to assess a broad wet AMD population, including hard-to-treat patients with severe disease ...

The California Institute for Regenerative Medicine has funded Keck School of Medicine of USC translational research advancing ...

Recommendations emphasize monitoring rapid keratoconus progression in patients under 18.

Melt Pharmaceuticals announced positive results from its Phase 3 study of MELT-300, a non-IV, non-opioid tablet for ...

SpyGlass Pharma completed enrollment in a Phase 1/2 trial evaluating its drug delivery platform for glaucoma and ocular ...

Key findings include reduced lesion growth, retinal tissue preservation, and improved visual function, demonstrating ...

Astellas said in a press release that the FDA comments in the CRL relate to proposed labeling language, not safety.

Emmecell announced positive Phase 1 extension study results for EO2002, a nonsurgical cell therapy for corneal edema. The ...

Gildeuretinol (ALK-001) received FDA Rare Pediatric Disease and Fast Track designations for Stargardt disease, highlighting ...